Ardelyx Priced, Nasdaq: ARDX
Developing therapies to control the progression of late-stage kidney disease.
Industry: Health Care
First Day Return: +0.8%
Industry: Health Care
ARDX
Developing therapies to control the progression of late-stage kidney disease.
| IPO Data | |
|---|---|
| IPO File Date | 05/19/2014 |
| Offer Price | $14.00 |
| Price Range $13.00 - $15.00 | |
| Offer Shares (mm) | 4.3 |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 06/18/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Fremont, CA, United States |
| Founded | 2007 |
| Employees at IPO | 37 |
| Website www.ardelyx.com | |
IPO News for Ardelyx
Ardelyx (ARDX) Performance
